Viewing Study NCT01019395

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 1:18 PM
Ignite Modification Date: 2026-05-13 @ 8:02 PM
Study NCT ID: NCT01019395
Status: COMPLETED
Last Update Posted: 2019-11-13
First Post: 2009-11-23
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics
Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Gram Positive Bacterial Infection View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Gram Positive Infection View
None Concurrent Antibiotic Treatment View